A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Trial end date:
2021-03-24
Target enrollment:
Participant gender:
Summary
This randomized, multi-center, active-controlled, open-label, parallel-group study will
investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line
mCRC. Participants with mCRC are eligible for entry and cannot have received any prior
chemotherapy in the metastatic setting. The entire study duration is anticipated to be
approximately 7.5 years.